

FIRST TIME GENERIC APPROVAL

Brand Name	Migranal®
Generic Name	dihydroergotamine mesylate
Drug Manufacturer	Custopharm, Inc.

New Drug Approval

Dosage form(s): 4 mg/mL (1 mL Vial) Nasal Spray

Therapeutic equivalent code: AB

FDA Approval Date: February 28, 2020

Indications for Use

dihydroergotamine mesylate is indicated for:

- The acute treatment of migraine headaches with or without aura.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.